



Errata

To cite this article: (2010) Errata, Current Medical Research and Opinion, 26:8, 1826-1826, DOI: [10.1185/03007995.2010.495490](https://doi.org/10.1185/03007995.2010.495490)

To link to this article: <https://doi.org/10.1185/03007995.2010.495490>



Published online: 07 Jun 2010.



Submit your article to this journal [↗](#)



Article views: 343



View related articles [↗](#)

Errata

Correction to: Bruce A. Cohen and Victor M. Rivera. PRISMS – the story of a pivotal clinical trial series in multiple sclerosis. *Curr Med Res Opin* 2010; 26(4): 827-838, doi:10.1185/03007991003604018.

The authors have reported a minor correction that is required for Table 1 of this article. The dosage details of the comparator for the EVIDENCE study were incorrect. The corrected table is provided below.

Table 1. Pivotal clinical studies of the efficacy and safety of interferon beta-1a.

Study	Year of start	Duration	Patients	IFN beta-1a sc dosing	Comparator
ETOMS ^{6,7*}	1995	2 years	At risk of conversion to clinically definite MS	22 µg once weekly	Placebo
EVIDENCE ^{8,9}	1999	16 months	RRMS	44 µg three times weekly	im IFN beta-1a, 30 µg once weekly
Nordic SPMS ¹⁰	1995	2 years	SPMS	22 µg once weekly	Placebo
OWIMS ¹¹	1995	3 years	RRMS	22 or 44 µg once weekly	Placebo
PRISMS-2 ^{1*}	1994	2 years	RRMS	22 or 44 µg three times weekly	Placebo
PRISMS-4 ^{4*}	1996	2 years	RRMS	22 or 44 µg three times weekly	–
PRISMS LTFU ⁵	2001	1 visit	RRMS	Any/no DMD	–
REGARD ¹²	2004	2 years	RRMS	44 µg three times weekly	Glatiramer acetate, 20 mg once daily
SPECTRIMS ^{13,14}	1994	3 years	SPMS	22 or 44 µg three times weekly	Placebo

*Rated as Class I evidence¹⁵.

DMD = disease-modifying drug; ETOMS = Early Treatment Of Multiple Sclerosis; im = intramuscular; LTFU = long-term follow up; MS = multiple sclerosis; OWIMS = Once Weekly Interferon for MS; PRISMS = Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis; REGARD = REbif vs Glatiramer Acetate in Relapsing MS Disease; RRMS = relapsing–remitting MS; SPECTRIMS = Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS; SPMS = secondary progressive MS; sc = subcutaneous.

Correction to: Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study.

In the original article published in *Curr Med Res Opin* 2010; 26(5):1083-1089, Dr. Frank Dellanna's name incorrectly appeared in the author list as 'Dellana'. We are happy to correct this error.